Signals
within.

Research chapter / orientation

A map for connected systems

The question behind the exhibit

An ordinary breath, a microbial metabolite, a pineal hormone and a vivid inward experience seem far apart. Biology supplies several real connections among them. Understanding those connections requires attention to scale: a molecular structure, a cellular response, an organ circuit, a person’s experience and a clinical outcome each answer different questions.

This report follows six threads: the indole molecular family; gut–brain communication; breathing and autonomic measurements; pineal and circadian biology; specific contemplative traditions; and psychedelic therapeutic research. It asks where the threads meet and which proposed bridges remain untested.

Three relationships to keep distinct

Chemical kinship. Related molecules can share an indole scaffold while differing in substitutions, transport, metabolism, receptors and effects. A molecular resemblance is neither a complete biosynthetic pathway nor evidence of an identical experience. [M1, M2, M3, M4, M5, M6, M7, M8, M9, M10]

Physiological communication. Neural signals, hormones, immune mediators and microbial products can participate in body–brain communication. They do not form one freely circulating pool of serotonin. The compartment and direction of signaling matter. [G2, G5, G6]

Experience and interpretation. An interior world can feel profound and influence a life. A report describes how it appeared and what it meant; identifying a molecular cause or establishing an independently existing realm requires further evidence. Traditions and clinical studies approach these questions differently. [T6, C12]

How to read the evidence

The report uses original research, official molecular records, regulatory documents, historical texts and museum collections. The role of each is stated in the chapter registers.

Cell and animal experiments can reveal mechanisms while leaving human benefit unresolved. Human physiological studies can show an acute change without establishing lasting improvement. Randomized clinical trials test specific packages in selected populations, against particular comparators and over defined follow-up periods. Sacred texts and artworks document practices, beliefs and representation; they are not biochemical experiments.

The models are explanatory schematics. Their colors and motion do not measure serotonin, vagal activity, microbial health or consciousness. Links beside them lead to designs and limits. The molecular images reproduce official PubChem depictions.

The practical destination

The aim is a more useful understanding of bodily regulation and mental health. Comfortable breathing, sleep timing, activity, connection and appropriate care can have value without needing a dramatic biochemical story. Psychedelic research can be examined without making drug use a recommendation or an expected stage of personal development.

Evidence reviewed October 25, 2026. This is a narrative research synthesis rather than a preregistered systematic review. Clinical and regulatory findings retain dates and populations. No personal measurements or health information are collected.

Research chapter / chemistry

The indole family

What the rings show

The family resemblance is real. Indole consists of a six-membered benzene ring fused to a five-membered nitrogen-containing ring. Fused rings share two neighboring atoms and their bond. One nitrogen belongs to the five-membered ring; the scaffold contains eight carbons and one nitrogen. [M1]

Tryptamine adds an ethylamine side chain at indole’s 3-position: two carbons leading to an amine. This is a useful reference for comparison. An indole ring alone is not a psychedelic signature, and a tryptamine scaffold does not establish a therapeutic effect or particular experience. Attached groups, their positions and biological handling matter. [M2]

Tryptophan belongs on the map

L-tryptophan is an essential amino acid with an indole-containing side chain. Its amino-acid portion distinguishes it from tryptamine: the side chain leads to a carbon carrying an amino group and a carboxyl group. The biological L form has defined stereochemistry. [M3]

A precursor relationship differs from a visual resemblance. Tryptophan participates in several processes; eating more does not selectively direct production toward a desired molecule in a chosen organ. Transport, enzymes, competing pathways and feedback also need investigation.

Serotonin and melatonin

Serotonin is 5-hydroxytryptamine, or 5-HT. Relative to tryptamine, it has a hydroxyl group at the indole ring’s 5-position. Its function depends on location, timing and the receptors expressed by receiving cells. The abbreviation is a chemical name, not a happiness measurement. [M4]

Melatonin is N-acetyl-5-methoxytryptamine. It contains a methoxy group at position 5 and an acetylated side-chain nitrogen. These changes matter even though the indole remains recognizable. The pineal chapter follows its enzymatic relationship with serotonin. Chemical ancestry does not make them the same biological signal. [M5]

DMT, psilocin and psilocybin

DMT means N,N-dimethyltryptamine. Its two methyl groups attach to the side-chain nitrogen. Unlike serotonin, it has no ring hydroxyl group. Identifying a common scaffold should be followed by identifying those differences. [M6]

Psilocin is 4-hydroxy-N,N-dimethyltryptamine. It has DMT’s two nitrogen-bound methyl groups and a hydroxyl at ring position 4. Compared with serotonin, both the hydroxyl position and the nitrogen substitutions differ. [M7]

Psilocybin carries a phosphate-containing group at position 4. In the body it is converted to psilocin; the administered compound and active metabolite should therefore remain distinct in a study or diagram. [M8, M9]

Identities and formulas: PubChem [M1, M2, M3, M4, M5, M6, M7, M8]. Parent-compound drawings do not imply the same charge state in every biological fluid.

A receptor interaction requires more than visual similarity

Related compounds can interact with some of the same targets without having identical activity. Binding affinity concerns binding under specified conditions; activation concerns the response produced in an assay.

Rickli and colleagues compared tryptamines, including psilocin and DMT, at monoamine receptors and transporters. They found overlapping but differing interaction profiles. Chemical modifications therefore need investigation rather than treatment as decorative additions. Isolated-cell findings still cannot fully describe a human experience or clinical benefit. [M10]

In a 2019 PET study of eight healthy volunteers, estimated brain 5-HT2A receptor occupancy reached up to 72% after psilocybin. Occupancy and plasma psilocin were associated with reported intensity. This supports the receptor’s importance, while neither occupancy nor intensity measures insight, clinical improvement or access to an independently verified realm. [M9]

Which relationships does the scaffold support?

The common structure organizes the chemical map. It does not establish that all tryptamines are psychedelics, that serotonin functions as endogenous DMT or that melatonin and psychedelic states are interchangeable.

Likewise, structural comparison cannot establish a sequence from humming to gut serotonin and then to a pineal psychedelic state. Each proposed step needs evidence about biological change, route, concentration and effect. A visually plausible chain can contain untested links.

The interesting question survives this distinction: contemplative practice, bodily regulation and altered experience can be studied together without one molecule explaining everything.

Read the gallery in three layers

First identify the fused indole rings. Then locate differences: side chain, hydroxyl or methoxy group, nitrogen substitutions and phosphate. Finally ask what experiments show about conversion, transport, receptors and effects.

The gallery uses official PubChem two-dimensional depictions for the listed compounds. A comparison is not a conversion arrow: biosynthetic transformations are shown separately, with enzymes and tissue context.

Evidence register

Research chapter / gut-brain

Gut serotonin & the conversation within

Follow the route, not just the molecule

The gut–brain relationship is an exchange among tissues, nerves, microbes, immune cells and circulating signals. Three questions organize it: Who makes a molecule? Where can it travel? What response does it produce? A blood measurement, an intestinal-cell response, a nerve signal and a person’s well-being are different findings. Connecting them requires evidence at each step.

Most serotonin is made outside the brain

Yano and colleagues describe more than 90% of the body’s serotonin as synthesized in the gut, much of it by host enterochromaffin cells in the intestinal lining. This describes a serotonin pool, not a percentage of happiness or thought. [G1]

Serotonin is 5-hydroxytryptamine, or 5-HT. Its production begins with tryptophan, but tissues and enzymes matter. Côté and colleagues’ mouse experiments distinguished TPH1, expressed in enterochromaffin cells and pinealocytes, from TPH2, expressed in brainstem raphe neurons and neurons of the myenteric plexus. The latter belongs to the enteric nervous system. Disrupting the nonneuronal pathway did not eliminate the separate neuronal system. The gut itself contains distinct serotonin-producing compartments. [G2]

Pineal cells can synthesize serotonin locally. Abundant intestinal serotonin does not establish that it travels to, and concentrates within, the pineal gland. The circadian chapter follows that gland’s local serotonin–melatonin pathway. [G2]

A precursor can travel where serotonin does not readily go

Serotonin does not readily cross the intact blood–brain barrier. Peripheral and brain-neuronal serotonin are consequently not interchangeable supplies. Researchers have investigated specialized liposome and immune-cell systems to improve serotonin delivery to the brain in animals—an engineered delivery problem, rather than normal gut-to-brain circulation. This experimental work is not a clinical treatment. The pineal has different vascular characteristics and requires its own anatomical explanation. [G3]

Tryptophan, the precursor, can enter the brain through transport mechanisms shared with other large neutral amino acids. Classic rat experiments showed that brain tryptophan and serotonin depended partly on tryptophan’s relationship to competing amino acids in blood. The lesson concerns transport and biochemical context: one precursor in a meal is not a simple meter of brain serotonin. These experiments do not prescribe a human dietary or supplement treatment. [G4]

Microbes can influence the host’s production

In Yano and colleagues’ experiments, spore-forming bacteria from mouse and human microbial communities promoted serotonin biosynthesis by colonic enterochromaffin cells in mice. Microbial metabolites helped regulate the host pathway. This supports microbes influencing host-cell production; human-derived microbes tested in mice do not make the experiment a successful human treatment trial. [G1]

Enterochromaffin cells are active sensors. Bellono and colleagues showed in experimental preparations that they detect particular chemical stimuli, become electrically active and influence serotonin-sensitive sensory neurons. This offers a mechanism linking intestinal chemistry with neural signaling. It does not establish that every gut sensation is a serotonin signal or that increasing intestinal serotonin is invariably beneficial. Location, stimulus, receptor and response remain essential. [G5]

A nerve carries activity, not a circulating serotonin supply

An afferent pathway carries information toward the central nervous system; an efferent pathway carries commands away. An arrow labeled “vagus” should represent neural signaling.

Kaelberer and colleagues demonstrated a rapid sensory circuit in mice: particular enteroendocrine cells connected with vagal neurons and transmitted gut signals using glutamate. This expands the account beyond serotonin. Gut sensing includes fast neurotransmission as well as slower hormonal and other signals. One messenger need not explain every connection. [G6]

Bravo and colleagues found that Lactobacillus rhamnosus JB-1 altered regional brain GABA-receptor expression, stress-related physiology and some behavioral measures in mice. Several effects were absent after vagotomy. That implicated the vagus in this experimental setting; it did not establish that all microbes act through it or that the strain treats human anxiety. [G7]

A human translation provided a useful counterexample. Allen and colleagues tested JB-1 in an eight-week randomized, placebo-controlled crossover study involving 29 healthy men. It did not outperform placebo on measured stress-related and cognitive outcomes. This does not settle every microbiome intervention or patient population. It shows why a striking mouse result should retain its species label. [G8]

Stress, immunity and feedback

Borovikova and colleagues showed that electrical stimulation of the peripheral vagus reduced aspects of the inflammatory response to endotoxin in rats; related experiments examined acetylcholine’s effects on human macrophages. This influential experimental link between neural activity and inflammation does not establish that humming or meditation produces the same effect. Those practices require their own intervention and outcome evidence. [G9]

The direction can also run from stress toward the intestinal environment. In Bailey and colleagues’ mouse experiments, social disruption changed microbial community structure and was associated with inflammatory signaling. Antibiotic manipulation altered parts of that response. These findings concern a particular animal stress paradigm, not a diagnosis of a stressed person’s microbiome. They support studying feedback rather than assuming every problem begins in the gut. [G10]

What human interventions have demonstrated

Diet can change biology without proving a particular psychological benefit. Wastyk and colleagues analyzed 36 healthy adults, 18 per group, in a prospective comparison of high-fiber and fermented-food dietary patterns within a 17-week protocol. The fermented-food group showed increased microbial diversity and reduced inflammatory markers. The study did not demonstrate increased brain serotonin, pineal activation or treatment of depression. A finding in one measured system should not silently become a claim about another. [G11]

A 2023 randomized pilot trial of adjunctive probiotics for depression examined a more directly clinical question. Of 50 included participants, 49 received an intervention and entered intention-to-treat analysis: 24 probiotic and 25 placebo. Participants continued antidepressant treatment. Acceptability, tolerability and preliminary symptom-effect estimates supported further study; this was not a definitive efficacy trial. A multistrain product in an add-on setting cannot justify replacing established treatment or generalizing to any probiotic. [G12]

Keep the missing steps visible

The strongest map links microbial activity, intestinal cells, sensory nerves, circulating signals and immune responses while labeling animal mechanisms and demonstrated human outcomes separately. It does not establish a sequence in which a “better microbiome” creates more brain serotonin, a stronger vagus and higher consciousness.

The relationship is compelling because the body has several interacting ways to sense its internal condition. The research question is which intervention changes which pathway, for whom, over what period, and with what meaningful outcome. Preserving those distinctions makes the connection more useful.

Evidence register

Research chapter / breath

Breath, humming & the vagus

A route into regulation

Breathing continues automatically, yet people can deliberately change its rhythm. That makes it a practical way to investigate interactions among attention, sensation and bodily state. A change in breathing can matter without being a complete explanation of mental health.

The vagus connects the brainstem with organs including the heart, lungs and intestines. It participates in communication between bodily processes and systems involved in behavior and mood. Medical vagus nerve stimulation uses electrical signals to engage circuitry. These connections make the nerve relevant, while the effect still depends on the organ and intervention. [V1]

“Stimulating the vagus” can mean programmed electrical stimulation, changing cardiac parasympathetic influences, engaging sensory pathways or simply feeling calmer. These claims require different measurements. A relaxed feeling is a real experience; it is not a direct recording of nerve activity or a microbiome test.

Rhythm can connect practices with different meanings

In a 2001 study of 23 healthy adults, Bernardi and colleagues examined spontaneous breathing, ordinary speech, the Ave Maria and a yoga mantra. Both rhythmic recitations slowed respiration toward six breaths per minute and synchronized cardiovascular oscillations. Baroreflex sensitivity—the responsiveness of a blood-pressure regulation mechanism—also increased. [V2]

This identifies a physiological feature shared by practices with different religious meanings. It does not establish one ideal rate for everyone or verify either tradition’s theology. A rhythmic phrase can organize breathing while carrying personal, communal or spiritual significance.

Humming changes several processes

A hum combines airflow, vocal vibration, hearing and attention. Its effects deserve investigation across these processes.

A 2002 experiment in ten healthy participants found approximately a 15-fold increase in nasal nitric oxide during humming compared with quiet exhalation. The researchers investigated oscillating airflow and gas exchange between the paranasal sinuses and nasal cavity. This was an acute nasal measurement—not a fifteen-fold increase in vagal activity, blood nitric oxide or therapeutic benefit. [V3]

A 2025 pilot involving 16 healthy adults compared rest, slow-paced breathing and humming breathing. Both breathing conditions increased several HRV measures relative to rest. Participants reported greater relaxation during rest and both breathing conditions than at baseline. There was no significant humming–paced-breathing difference in HRV or affect measures. [V4]

The comparator matters. This pilot supports further investigation, but does not demonstrate a unique vibration-driven vagal treatment or a durable disease benefit. Humming can remain a useful, enjoyable practice without every effect being assigned to the vagus.

What “vagal tone” can tell us

Heart-rate variability, or HRV, describes variation in the intervals between heartbeats. RMSSD summarizes successive interval differences. Respiratory sinus arrhythmia, or RSA, describes respiration-linked fluctuations. High-frequency HRV captures power within a conventional frequency band. Under suitable conditions, these measures help researchers investigate cardiac parasympathetic regulation.

Breathing rate and depth also affect the heart’s respiratory pattern. Current cardiovascular research guidance recommends recording respiration and reporting relevant measurement conditions. A wrist-derived score, an ECG-derived measure and a neural recording are different forms of evidence. None is a universal whole-body “vagus strength” score. [V6]

Frequency bands create a particular trap. In a 12-volunteer experiment, Bernardi and colleagues found that speech and breathing changes altered HRV spectra. Slow breathing could move respiratory fluctuations into the conventional low-frequency band. Equating increased low-frequency power with increased sympathetic activity could therefore mislead. [V5]

An HRV increase during slow breathing may partly reflect the maneuver itself. Training effects also need measurements outside practice under comparable conditions. Larger oscillations during an exercise do not automatically establish permanent autonomic improvement.

Cardiac measures likewise cannot establish microbial composition, intestinal serotonin production or activity in every gastrointestinal pathway. Those questions need their own measurements.

Psychological outcomes matter in their own right

A 2023 randomized study enrolling 108 participants compared brief daily breathing exercises with mindfulness meditation over approximately a month. Breathwork, particularly an exhalation-emphasizing approach, showed advantages in positive affect and respiratory-rate change. Both meditation and breathwork were associated with reduced state anxiety after practice. The study found no significant HRV differences across conditions. [V7]

This illustrates a useful distinction: a psychological benefit need not be explained by a demonstrated HRV increase. The findings concern short-term practice in a recruited sample, rather than an interchangeable effect of every breathing method.

Another trial assigned 276 adults with anxiety disorders to an eight-week mindfulness-based stress reduction program or escitalopram; 208 completed the trial. MBSR met the prespecified noninferiority criterion on clinician-rated anxiety severity. The intervention was a structured program, involving substantially more than occasional humming or an unguided minute of attention. [V8]

These studies support suitable practices among a broader range of mental-health options. They do not establish that benefit arises from increased gut serotonin or a psychedelic-like state. Clinical outcomes and biological mechanisms remain separate research questions.

Medical stimulation is a distinct intervention

Clinical VNS uses specified equipment, stimulation parameters, patient selection and monitoring. Its benefits and risks are evaluated for particular conditions.

The FDA approved the Vivistim paired-VNS system in 2021 for rehabilitation in selected people with chronic ischemic stroke and moderate-to-severe arm impairment. It pairs rehabilitation movements with electrical stimulation delivered through an implanted lead. That evidence concerns a device, population and treatment context. [V9]

Results from electrical VNS cannot simply be transferred to humming, nor are implanted and through-the-skin systems interchangeable. Ask which intervention was tested, against which comparator and on which outcome.

A gentle experiment in attention and comfort

For everyday stress management, a practical aim is to explore whether a comfortable rhythm helps someone settle, without requiring a biomarker.

Sit or stand comfortably and let breathing move gently. There is no need to force depth or pursue a rigid target. NHS guidance emphasizes regular, comfortable breathing and allows counting if helpful. A quiet hum on an easy exhalation can be an optional variation. Return to ordinary breathing if uncomfortable or lightheaded; avoid straining, rapid breathing or prolonged holds. [V10]

Notice whether the practice feels pleasant, neutral, irritating or activating. A particular response is neither a moral achievement nor a failure. A subjective check-in is useful as an observation, rather than a diagnosis.

Meditation is not universally comfortable. NCCIH notes incomplete safety research and the possibility of negative experiences. Persistent symptoms warrant appropriate care; a suitably trained teacher or clinician can help adapt practice to the person. [V11]

A network rather than one control knob

Deliberate behavior changes respiration and attention; these interact with cardiovascular and sensory processes; repeated practice may support coping. Gut–brain signaling and circadian biology contribute other relationships, examined in their own chapters.

Understanding a practice well enough to use it intelligently does not require reducing every benefit to serotonin or every pleasant sensation to a vagal measurement.

Evidence register

Research chapter / pineal

Light, time & pineal chemistry

Sources, signals and experience

Serotonin and melatonin are related molecules, and the pineal is an important place where that relationship becomes useful. Its role becomes clearer when we separate the source of a molecule, the tissue using it, the signal controlling that tissue and the experience someone reports.

Local chemistry produces a timing signal

Classic isotope experiments showed that isolated rat pineal glands could make labeled melatonin from labeled tryptophan. Norepinephrine, also called noradrenaline, stimulated the process. Organ culture demonstrated local biochemical capacity rather than a requirement for serotonin arriving from the gut. It did not test human mystical experience or a dietary intervention. [P1]

The principal pathway is:

Tryptophan → 5-hydroxytryptophan → serotonin → N-acetylserotonin → melatonin.

AANAT catalyzes serotonin’s conversion to N-acetylserotonin. ASMT, also called HIOMT, carries out the following methylation. A 2021 study of rat pineal cells and tissue found that released serotonin could act locally to enhance norepinephrine-driven melatonin secretion. Serotonin alone did not trigger secretion under the tested conditions. The gland contains interacting local signals. [P2]

The blood–brain barrier needs an anatomical qualification

Brain and peripheral serotonin are not freely interchangeable supplies. Yet describing the pineal as sealed behind the ordinary blood–brain barrier also oversimplifies its anatomy. Tracer experiments demonstrated highly permeable, fenestrated capillaries in the mouse pineal. Its vascular organization can differ from surrounding neural tissue. [P3]

This does not establish a gut-to-pineal concentration mechanism. The gut’s proportion of total-body serotonin cannot identify the source inside another tissue. That requires transport, tracing and metabolic evidence. Local pineal synthesis is established; the evidence here does not establish that gut serotonin concentrates in the pineal.

Light information reaches a neural clock

The canonical pathway begins with retinal light information reaching the suprachiasmatic nucleus (SCN), the central circadian pacemaker. Its influence reaches the pineal through the hypothalamic paraventricular nucleus, upper thoracic spinal sympathetic neurons and the superior cervical ganglion. Viral tracing in rats demonstrated this multisynaptic circuit. [P4]

The final sympathetic input releases norepinephrine to promote nighttime pineal melatonin production. The established light–pineal route is therefore sympathetic, rather than a direct vagal switch. This is also a reminder that sympathetic activity is not inherently harmful: effects depend on organ, circuit and timing.

Light synchronizes the circadian system and can suppress melatonin during the biological night. A diagram should not show light directly turning melatonin on. Nighttime endocrine output communicates temporal conditions through a coordinated system.

The environment can change hormonal timing

A randomized crossover laboratory study followed 12 healthy young adults reading a light-emitting eReader or a printed book before bed. Each condition involved four hours of evening reading over five consecutive evenings. The eReader condition suppressed melatonin, delayed circadian timing and changed sleep and next-morning alertness. [P5]

This human experiment demonstrates environmental influence on endocrine timing. Its intensive schedule and small sample cannot predict every screen, brightness, exposure duration or individual response.

Melatonin is a hormonal timing signal. Its chemical relationship with serotonin does not make the molecules functionally interchangeable, and shared tryptamine chemistry does not make melatonin an endogenous psychedelic.

Endogenous DMT: findings and open questions

DMT has been reported in human biological samples, including a 1965 investigation of blood and urine. Detection in a sample does not identify a human pineal concentration, a moment-to-moment brain exposure or a subjective function. Historical analytical methods also need interpretation in their period. [P6]

In 2013, researchers used liquid chromatography–tandem mass spectrometry on rat pineal-region microdialysate and reported DMT detection. This was analytical evidence in an animal preparation. It was not a measurement of psychedelic concentrations in the living human pineal, nor evidence that meditation, dreaming or near-death experiences arise from pineal DMT release. [P7]

A 2019 study measured extracellular DMT in the visual cortex of living rats, including animals whose pineal glands had been removed. DMT remained detectable after pinealectomy. The researchers also examined relevant enzyme transcripts in rat and human tissues. These findings support investigating endogenous DMT while arguing against treating the pineal as a necessary or exclusive source in rats. Human gene-expression evidence is not a measurement of release during experience. [P8]

The enzymology remains complicated. A 2023 study found that deleting INMT in rats did not eliminate measured tryptamine-dependent methylation activity; products in those assays were neither DMT nor its immediate methylated precursor. Recombinant human and rabbit INMT behaved differently from rat INMT. This identifies species and assay questions, rather than disproving every endogenous-DMT report. [P9]

Experience deserves care; mechanisms need measurements

A vivid interior realm can be reported honestly while its mechanism remains unresolved. Establishing a chemical explanation requires connecting the proposed substance, location, concentration, timing and experience. Finding a molecule somewhere in the body is one part of that chain.

Animal research cannot determine an experience’s spiritual significance. Meaning, phenomenology and biochemical mechanism can each be investigated without forcing one kind of evidence to answer every question.

The evidence does not currently establish a human pineal psychedelic reservoir, a DMT explanation for ordinary dreams or an endocrine route to another world. It leaves legitimate questions about endogenous compounds and neural function.

Work with measurable rhythms

Practical circadian habits include regular sleep opportunities, a consistent sleep–wake schedule, daytime outdoor activity when possible, quieter and dimmer evenings, and a quiet, cool, dark sleep environment. NHLBI includes these in healthy-sleep guidance. Persistent sleep difficulties warrant assessment. These habits shape environmental and behavioral conditions; they are not a method for accumulating psychedelic compounds. [P10]

The established coordination is already remarkable: light supplies timing information, neural circuits convey it, pineal cells transform local precursors, hormones communicate timing, and behavior changes the conditions under which those systems operate.

Evidence register

Research chapter / traditions

Practices, traditions & interior worlds

Many practices, several purposes

Breath, attention, sound and bodily awareness appear together in many contemplative practices. That convergence makes them worth investigating without assuming every tradition used the same technique, goal or explanation.

These examples come from particular South Asian yogic, Buddhist and Jain contexts. They are not a complete account of “Eastern spirituality.” Texts and images describe liberation, devotion, ethical conduct, concentration and transformations of experience. Modern research can test selected processes while recognizing those meanings.

Three questions remain useful: What does a practitioner experience? How does a tradition interpret it? What mechanism did a study actually test?

Bhrāmarī within a yogic discipline

The Haṭha Yoga Pradīpikā names bhrāmarī among its breathing practices. Verse 2.68 describes insect-like sound during breathing and associates it with an ecstatic or blissful mental condition. It documents a historical relationship among sound, breath and altered experience, without naming the vagus, serotonin, microbiome or DMT. [T1]

The vocabulary belongs to a larger framework of disciplined practice, instruction and spiritual attainment. Equating every reference to prāṇa or bodily channels with a modern anatomical structure goes beyond the text. Historical instructions also should not be copied directly into a clinical protocol. Modern humming studies ask different, measurable questions.

Buddhist breath mindfulness extends beyond relaxation

MN 118, the Ānāpānasati Sutta, develops breath attention through a structured sequence. The practitioner recognizes long and short breaths, attends to bodily experience, cultivates calm, observes mental activity, and contemplates change and relinquishment. These practices are connected with mindfulness and awakening in a monastic setting. [T2]

A laboratory might measure respiration, attention or stress during one component. That would not test the text’s complete account of liberation. Calm is situated within observation and changes in one’s relationship with experience, rather than being an isolated target.

An unusual state is not the only criterion

MN 36, the Mahā Saccaka Sutta, recounts the Buddha’s search through demanding practices and reconsideration of meditative pleasure. Successive jhānas involve changes in rapture, pleasure, concentration and equanimity. The narrative distinguishes impressive attainments from the liberation sought. [T3]

This offers a historical reason to separate an unusual state from a completed transformation. An absorption, vision or feeling of certainty need not be the final criterion of development, even within a tradition recognizing exceptional experiences.

The text is a religious account, not a measurement of neurotransmitter release. Understanding its own categories comes before translating them into scientific hypotheses.

Mantra includes meaning

Patañjali’s Yoga Sūtras 1.27–1.29, in Swami Vivekananda’s translation and commentary, link Om with repetition and contemplation of its meaning. Sound, attention, association and theology appear together, rather than a prescription for one acoustic frequency. [T4]

A comparison with humming is useful but incomplete. Meaning, intention, instruction and setting can change the activity. A physiological response during chanting would not establish every theological explanation attached to it.

Ethical and interpersonal aims

The Buddhist Karaṇīya Mettā Sutta joins peaceful conduct with goodwill toward other beings. Its concerns include honesty, gentleness, freedom from hostility and cultivation of care. These are interpersonal commitments as well as inward practices. [T5]

Feeling peaceful during a session and responding patiently in a difficult relationship are different outcomes. Both matter; one should not simply be assumed from the other. A broader investigation considers conduct, relationships and everyday functioning alongside sensations.

Similar postures, different traditions

The Met’s Jain collection shows why images need precise labels. Jain jinas or tīrthaṅkaras can sit in poses resembling Buddhist meditation imagery, while belonging to a distinct framework of renunciation, liberation and nonviolence. A shared posture does not establish identical doctrine. [T7]

An Encampment of Yogis, painted around 1660 in the Deccan, places practitioners within a social setting. The image counters the idea of a universally isolated meditator, while remaining a representation rather than a measurement of anyone’s mental state. [T8]

A sixteenth-century Sri Lankan Buddha image represents another particular place, period and religious identity. It is not a generic illustration of a measured “serotonin state.” [T9]

Interior worlds deserve careful description

Luminous imagery, altered selfhood, unusual bodily sensations or an apparently vast inner space can be deeply significant. Taking the report seriously does not require an immediate decision about what exists beyond it.

Saying an experience felt like another world records phenomenology: how it appeared. It does not by itself identify a molecule, demonstrate DMT release or establish an independently existing realm. These are further questions.

The Varieties of Contemplative Experience study interviewed 60 Buddhist practitioners and 32 experts, with overlap between groups. It documented perceptual, emotional, bodily, self-related and functional changes, including difficulties. Recruitment deliberately sought people able to report meditation-related challenges. It was not a representative survey from which to estimate prevalence. Interpretation and impact depended on personal, practice and social circumstances. [T6]

Support matters when experiences become persistently distressing or disrupt sleep and everyday functioning. Intensity alone does not establish spiritual advancement.

States and lasting development

A state describes experience during a period: absorption, calm, imagery, altered bodily boundaries or emotion. A trait concerns a more persistent pattern, such as attentional habits, reactivity, compassion or conduct across situations. Distinguishing them does not imply one brief practice guarantees lasting change.

“Higher” can also mean several things: more intense, clearer, less distressing, more compassionate or more functional. Useful questions identify the criterion, observer and timescale.

The inquiry can remain open without assuming a predetermined evolutionary destination or a single molecule underlying spiritual life. It invites closer study of how bodies, practices, meanings and environments participate in experience—and which changes help people live well.

Evidence register

Research chapter / therapy

Therapeutic potential & clinical evidence

Take experience seriously, then ask what it establishes

Vivid interior imagery, altered time, unity or an apparently autonomous presence can change someone’s understanding of themselves. The experience’s significance and its explanation are separate questions.

In a controlled study of 36 healthy, spiritually interested volunteers, Griffiths and colleagues found that psilocybin could occasion experiences rated personally meaningful and spiritually significant, with changes reported at follow-up. This selected population received substantial support. Questionnaires and observer reports document experience and attributed meaning; they cannot determine whether a perceived realm exists independently. [C12]

Clinical research asks another question: can an intervention reliably reduce suffering or improve functioning, for whom, for how long and with what harms?

What controlled depression trials show

Major depression, 2023. Raison and colleagues randomized 104 adults to psilocybin or niacin, with psychological support. At day 43, the between-group difference in MADRS depression-score change was −12.3 points, favoring psilocybin (95% CI −17.5 to −7.2). MADRS ranges from 0 to 60; higher scores indicate greater severity. The trial excluded histories of psychosis or mania and other higher-risk conditions. No serious treatment-emergent adverse events occurred, but overall and severe adverse events were more frequent with psilocybin. Six weeks cannot establish lifelong benefit or safety for excluded populations. [C1]

Treatment-resistant depression, 2022. Goodwin and colleagues enrolled 233 adults in a dose-finding trial with psychological support. At three weeks, the higher studied-dose group improved more than the very-low-dose comparison group: MADRS difference −6.6 points (95% CI −10.2 to −2.9). Adverse events occurred in 179 participants, or 77%, across the trial, including headache, nausea and dizziness. Suicidal ideation, behavior or self-injury occurred across groups. Deterioration deserves measurement alongside improvement. [C2]

An established-treatment comparison, 2021. A trial of 59 adults compared psilocybin with escitalopram, with psychological support in both groups. At six weeks, there was no significant difference on the prespecified primary outcome, QIDS-SR-16 depression-score change. Several secondary outcomes favored psilocybin, but comparisons were not adjusted for multiple testing. The study established neither superiority on its primary measure nor equivalence. [C3]

Different populations, comparators, outcomes and follow-up periods prevent a simple drug leaderboard.

What 2026 research adds

An NHS feasibility trial randomized 60 adults with treatment-resistant depression, thirty per group, to psilocybin or placebo with psychological support. Primary aims concerned recruitment, retention and measurement feasibility. Secondary analyses found a −10.41-point MADRS difference at three weeks (95% CI −14.86 to −5.95). Among 23 assessed participants, all thirteen in the psilocybin arm and seven of ten placebo recipients correctly guessed allocation. Expectancy may explain part of the observed difference. This small, single-site study supports a larger confirmatory trial. [C5]

A 2026 phase IIa DMT trial randomized 34 adults, seventeen per group, with moderate-to-severe major depression. Intravenous DMT or placebo accompanied psychological support. At two weeks, the MADRS difference favored DMT by −7.35 points (95% CI −13.62 to −1.08). Adverse events were mostly mild or moderate; none was serious. Later follow-up extended to approximately three months, but the subsequent phase was open-label and participants could receive active treatment. Later improvement therefore was not a continuing blinded placebo comparison. [C4]

A brief acute effect can precede longer psychological change. Establishing that change requires measurements after the experience, including relapse, worsening and additional care.

Setting is part of the intervention

A participant undergoing a powerful perceptual change may infer active treatment; staff may make the same inference. Expectations can influence reports, encounters and subsequent care.

Screening, preparation, monitoring, staff attention and follow-up also form part of the treatment package. The contribution of each remains a research question. Results from that package cannot automatically be assigned to a molecule in an unsupported setting.

FDA’s July 2026 final guidance, replacing the 2023 draft, addresses functional unblinding, expectancy, psychological interventions and durability. A rigorous investigation must examine sustained benefit and safety over a period appropriate to a potentially recurrent condition. [C6]

The question extends beyond whether a session was powerful: symptoms, sleep, relationships, work and functioning all deserve follow-up.

Plasticity is a mechanism to investigate

Ly and colleagues found structural and functional changes after psychedelic exposure in cultured neurons and animal systems, including changes in branching, spines and synaptic function. These preclinical results support hypotheses about plasticity and drug development. They do not establish repair in every exposed human brain, universal benefit from new connections or a necessary role for a subjective experience. [C8]

Plasticity is capacity for change. What is learned, the environment and subsequent experience influence whether change is useful. Clinical outcomes must establish therapeutic value.

Shared tryptamine chemistry likewise does not establish that depression is a shortage of psychedelic compounds or that indiscriminately increasing serotonin improves mental health.

Screening and support matter

NCCIH describes potential adverse effects including anxiety, panic, increased heart rate or blood pressure, nausea and persistent psychiatric disturbances. It cautions against use in psychotic conditions and certain severe psychiatric conditions. Screened-trial safety findings cannot be generalized to everyone or to unregulated products. [C10]

A history of mania or psychosis, cardiovascular concerns and current medicines can materially change decisions. Medication changes in a research protocol are supervised procedures, not instructions for readers to stop treatment.

An intense altered state may also affect someone’s ability to evaluate situations or communicate boundaries. Clinical care should preserve informed consent, dignity and accountability.

Development activity is not approval

U.S. status checked October 25, 2026: federal sources reviewed describe psilocybin and N,N-DMT as investigational therapeutic compounds. NIH identifies psilocybin’s Schedule I status; DEA’s DMT fact sheet identifies no approved U.S. medical use. State-regulated services and FDA approval of a medicine are separate questions. [C10, C11]

FDA announced priority vouchers in April 2026 for companies studying psilocybin for depression and a separate compound for PTSD. Such actions support development and potentially faster review. They are not an approval or an efficacy finding; the announcement emphasizes clinical evaluation. [C7]

Relief does not require an extraordinary state

People seeking help can discuss symptoms, sleep, substance use, medical history and preferences with a qualified clinician. NIMH describes psychotherapy, medication and appropriate brain-stimulation treatments as depression-care pathways. Regular meals, physical activity, social connection and sleep can support care. Medication decisions belong with the prescriber. [C9]

Contemplative practices and stress-management skills may have value while persistent or disabling symptoms still warrant assessment. A practical goal can be flexible attention, restorative sleep and more ways to respond to distress.

Psychedelic research makes an important possibility visible: a relatively brief intervention may sometimes precede meaningful psychological change. Determining who benefits, how to sustain improvement and how to prevent harm requires further work. Participation or extraordinary experience need not become an expectation or a measure of human advancement.

Evidence register